Prelude Therapeutics (PRLD) Return on Equity (2020 - 2026)

Prelude Therapeutics has disclosed Return on Equity across 7 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Prelude Therapeutics, up from 0.02% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.02% in Q3 2025.
• The 5-year median for Return on Equity is 0.01% (2023), against an average of 0.01%.
• Across the five-year window, Return on Equity changed 0 bps in 2022 and fell 1 bps in 2025, its largest moves.
• Prelude Therapeutics' Return on Equity stood at 0.01% in 2022, then climbed by 7 bps to 0.01% in 2023, then tumbled by 74 bps to 0.01% in 2024, then plunged by 69 bps to 0.02% in 2025, then grew by 21 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.02% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.